The Recall Desk

Recalls

All US Product Recalls

Searchable archive of product recalls from the FDA, USDA FSIS, CPSC, NHTSA, and EPA — translated into plain English, severity-scored from objective criteria, and always linked back to the original government notice.

How to read this listing

Every recall on this list has been scored 1–5 against an objective rubric from the agency’s own classification, presence of reported injuries or deaths, distribution scope, and hazard type. The colored severity badge on each card is the score — 5 (Critical) means the agency’s own highest classification or reported deaths or serious injuries, 4 (Severe) means significant injury or hospitalization risk, and 3 (High) means a known hazard with no confirmed harm yet. Filter to 3+ (High and above) if you want to skip routine Class-III notices.

The agency chips above control which streams are visible. FDA spans food, drugs, and medical devices. USDA FSIS is meat, poultry, and processed egg products. CPSC is household consumer products. NHTSA is vehicles, tires, and child seats. Nationwide on a card means the recall affects every US state — most do — while a state list means distribution was limited.

Click any recall to see the full summary, affected lot codes and model numbers, the agency’s own classification, and a direct link back to the original government notice for verification.

Filters

Agency

Category

Minimum severity

Clear filters

14251–14275 of 18001

  • SevereFDA (Drugs)·D-655-2015·2015-04-29

    Attix Pharmaceuticals Recalls Estradiol Cypionate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Estradiol Cypionate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Estradiol Cypionate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-676-2015·2015-04-29

    Attix Pharmaceuticals Recalls Floxuridine Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of Floxuridine active pharmaceutical ingredient distributed between January 2012 and February 2015 due to potential penicillin cross-contamination.

    Product
    Floxuridine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-578-2015·2015-04-29

    Attix Pharmaceuticals Recalls Chlorobutanol Hemihydrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Chlorobutanol Hemihydrate pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Chlorobutanol Hemihydrate pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-668-2015·2015-04-29

    Attix Pharmaceuticals Recalls Everolimus API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of everolimus active pharmaceutical ingredient distributed between January 2012 and February 2015 due to potential penicillin cross-contamination.

    Product
    Everolimus active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-757-2015·2015-04-29

    Attix Pharmaceuticals Recalls Levodopa API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Levodopa active pharmaceutical ingredient lots distributed between January 2012 and February 2015 due to potential penicillin cross-contamination during repackaging.

    Product
    Levodopa or L-Dihydroxyphenylalanine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-493-2015·2015-04-29

    Attix Pharmaceuticals Recalls 2-Deoxy-D-Glucose Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling 2-Deoxy-D-Glucose active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    2-Deoxy-D-Glucose active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, On
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-654-2015·2015-04-29

    Attix Pharmaceuticals Recalls Estradiol Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Estradiol (Non-Micronized) active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Estradiol (Non-Micronized) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-740-2015·2015-04-29

    Kanamycin Sulfate Recalled Due to Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Kanamycin Sulfate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Kanamycin Sulfate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-702-2015·2015-04-29

    Halobetasol Propionate Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Halobetasol Propionate active ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Halobetasol Propionate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-532-2015·2015-04-29

    Attix Pharmaceuticals Recalls Azelastine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Azelastine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Azelastine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-912-2015·2015-04-29

    Attix Pharmaceuticals Recalls Tadalafil Citrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Tadalafil Citrate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Tadalafil Citrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-624-2015·2015-04-29

    Attix Pharmaceuticals Recalls Dexamethasone Sodium Phosphate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Dexamethasone Sodium Phosphate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Dexamethasone Sodium Phosphate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-951-2015·2015-04-29

    Attix Pharmaceuticals Recalls Vecuronium Bromide Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Vecuronium Bromide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Vecuronium Bromide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-723-2015·2015-04-29

    Attix Pharmaceuticals Recalls Hydroxyurea Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Hydroxyurea active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Hydroxyurea active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-526-2015·2015-04-29

    Atazanavir API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Atazanavir active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Atazanavir active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-605-2015·2015-04-29

    Attix Pharmaceuticals Recalls Cyclobenzaprine HCI Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of Cyclobenzaprine HCI repackaged between January 2012 and February 2015 due to potential penicillin cross-contamination.

    Product
    Cyclobenzaprine HCI active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-797-2015·2015-04-29

    Attix Miconazole Nitrate Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Miconazole Nitrate active ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Miconazole Nitrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-812-2015·2015-04-29

    Attix Pharmaceuticals Recalls Naproxen Base Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Naproxen Base active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Naproxen Base active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-819-2015·2015-04-29

    Attix Pharmaceuticals Recalls Nitrofurantoin Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Nitrofurantoin active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging. The recall affects lots distributed nationwide to compounding pharmacies and research organizations.

    Product
    Nitrofurantoin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-599-2015·2015-04-29

    Attix Pharmaceuticals Recalls Colchicine API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling colchicine active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging. The product was distributed to compounding pharmacies and research organizations.

    Product
    Colchicine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-536-2015·2015-04-29

    Attix Pharmaceuticals Recalls Benazepril API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Benazepril active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Benazepril active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-539-2015·2015-04-29

    Attix Pharmaceuticals Recalls Benztropine Mesylate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Benztropine Mesylate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Benztropine Mesylate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-552-2015·2015-04-29

    Attix Pharmaceuticals Recalls Bupivacaine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Bupivacaine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Bupivacaine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-857-2015·2015-04-29

    Prednisolone API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Prednisolone Anhydrous Micronized API due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Prednisolone Anhydrous Micronized active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-851-2015·2015-04-29

    Attix Pharmaceuticals Recalls Potassium Phosphate Monobasic Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of Potassium Phosphate Monobasic distributed between January 2012 and February 2015 due to potential penicillin cross-contamination.

    Product
    Potassium Phosphate Monobasic pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide